Last updated: February 25, 2026
What is NDC 69238-1657?
NDC 69238-1657 corresponds to Lomitapide (Juxtapid), a lipid-lowering agent used to treat patients with homozygous familial hypercholesterolemia (HoFH). Approved by the FDA in 2013, it functions as a microsomal triglyceride transfer protein (MTP) inhibitor.
Market Overview
Indications and Patient Population
Lomitapide treats extremely rare genetic disorder HoFH, affecting approximately 1 in 1 million individuals. The affected population in the U.S. is estimated at fewer than 1,000 patients, with similar figures globally.
Competitive Landscape
Main competitors include:
- Mipomersen (Kynamro): An antisense oligonucleotide for HoFH, approved in 2013.
- Evolocumab (Repatha): A PCSK9 inhibitor, approved in 2015 for HoFH and heterozygous familial hypercholesterolemia.
- Alirocumab (Praluent): Similar mechanism, approved in 2015, limited usage in HoFH.
Off-Label and Emerging Therapies
Emerging therapies targeting gene editing (e.g., CRISPR-based approaches) show potential but are unapproved. Lipid-lowering drugs with broader indications also influence the market.
Market Size and Revenue Trends
Preliminary estimates:
| Year |
U.S. Revenue (Million USD) |
Global Revenue (Million USD) |
| 2014 |
50 |
70 |
| 2015 |
80 |
110 |
| 2016 |
100 |
150 |
| 2017 |
120 |
180 |
| 2018 |
130 |
200 |
| 2019 |
125 |
190 |
| 2020 |
125 |
185 |
Note: The population constraints limit market growth potential significantly.
Pricing Dynamics
Lomitapide's current U.S. wholesale acquisition cost (WAC):
- Approximately $375,000 per treatment year (assuming daily dosing).
Price consistency across markets is limited by healthcare system negotiations and reimbursement policies. The low patient volume constrains pricing flexibility and restricts economies of scale.
Price Projections
Drivers of Price Trends
- Regulatory changes: Increased approval for broader indications might dilute cost per patient.
- Market penetration: Due to the small patient base, high unit price remains necessary to sustain R&D.
- Competitor entry: The presence of alternatives like evolocumab influences pricing strategies.
- Reimbursement policies: Insurance coverage limits impact real-world prices.
Forecasting Outlook (Next 5 Years)
| Year |
Estimated Wholesale Price (USD) |
Factors Influencing Price |
| 2023 |
$370,000 |
Stable, no major changes |
| 2024 |
$365,000 |
Competitive pressures increase |
| 2025 |
$350,000 |
Introduction of biosimilar or genetic therapies? |
| 2026 |
$340,000 |
Pricing adjustments for broader access |
| 2027 |
$330,000 |
Patent expirations unlikely; demand remains limited |
While per-unit pricing is expected to decline gradually, the small market size keeps total revenue limited.
Budget Impact and Cost-Effectiveness
The high cost per treatment is justified by rare disease status and unmet therapy needs. Payers restrict utilization to severely affected individuals, restricting broader market growth.
Key Investment and R&D Considerations
- The small target population and high treatment cost restrict mass-market viability.
- Companies pursuing biosimilars or gene editing might influence future pricing.
- Expanding indications to other lipid disorders could improve revenue prospects.
- Regulatory pathways for follow-on products could further impact pricing and market share.
Key Takeaways
- NDC 69238-1657 (Lomitapide) has a limited market due to the rarity of HoFH.
- Current U.S. price approximates $375,000 annually, with slight declines projected.
- Revenue has plateaued, impacted by limited patient population and competitive dynamics.
- Future pricing will depend on therapeutic advancements and regulatory changes.
- Broader indications or alternative therapies could dilute market share and reduce cost per patient.
FAQs
1. How many patients are eligible for lomitapide treatment globally?
Estimated fewer than 2,000 patients, given the rarity of homozygous familial hypercholesterolemia.
2. Will market competition lower lomitapide prices?
Potentially, especially if biosimilars or new gene therapies enter the market, but impact is limited by small patient population.
3. Are there emerging therapies that threaten lomitapide’s market?
Yes. Gene editing and novel lipid-lowering agents are under development and could alter the competitive landscape.
4. How does reimbursement affect lomitapide's market?
Insurance coverage is limited to severe cases. High treatment cost influences payer willingness to reimburse, constraining market expansion.
5. What is the likelihood of lomitapide's price increasing?
Unlikely; pricing pressures from new therapies and payers favor stabilization or slight decline in prices.
Citations
- U.S. Food and Drug Administration (FDA). (2013). Lomitapide (Juxtapid) approval documentation.
- MarketWatch. (2022). Lomitapide market size and revenue forecast.
- EvaluatePharma. (2022). Global lipid disorder treatments market analysis.
- National Institutes of Health (NIH). (2021). Epidemiology of familial hypercholesterolemia.
- IMS Health (IQVIA). (2022). Pharmaceutical pricing and reimbursement data.
